Trial Profile
BRL29060A in Posttraumatic Stress Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Aug 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Post-traumatic stress disorders
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 13 Feb 2009 New trial record